Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

276 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.
Reddy KR, Govindarajan S, Marcellin P, Bernstein D, Dienstag JL, Bodenheimer H Jr, Rakela J, Messinger D, Schmidt G, Ackrill A, Hadziyannis SJ. Reddy KR, et al. Among authors: dienstag jl. J Viral Hepat. 2008 Feb;15(2):129-36. doi: 10.1111/j.1365-2893.2007.00901.x. J Viral Hepat. 2008. PMID: 18184196
Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group.
Davis GL, Lindsay K, Albrecht J, Bodenheimer HC Jr, Balart LA, Perrillo RP, Dienstag JL, Tamburro C, Schiff ER, Carey W, et al. Davis GL, et al. Among authors: dienstag jl. J Viral Hepat. 1994;1(1):55-63. doi: 10.1111/j.1365-2893.1994.tb00062.x. J Viral Hepat. 1994. PMID: 8790560 Clinical Trial.
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C; HALT-C Trial Group. Lok AS, et al. Hepatology. 2009 Jun;49(6):1828-37. doi: 10.1002/hep.22865. Hepatology. 2009. PMID: 19291787 Free PMC article. Clinical Trial.
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators. Di Bisceglie AM, et al. Among authors: dienstag jl. N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615. N Engl J Med. 2008. PMID: 19052125 Free PMC article. Clinical Trial.
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.
Lefkowitch JH, Schiff ER, Davis GL, Perrillo RP, Lindsay K, Bodenheimer HC Jr, Balart LA, Ortego TJ, Payne J, Dienstag JL, et al. Lefkowitch JH, et al. Among authors: dienstag jl. Gastroenterology. 1993 Feb;104(2):595-603. doi: 10.1016/0016-5085(93)90432-c. Gastroenterology. 1993. PMID: 8425703 Free article. Clinical Trial.
Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL, Perrillo RP, Tamburro CH, Goff JS, Everson GT, Silva M, Katkov WN, Goodman Z, Lau JY, Maertens G, Gogate J, Sanghvi B, Albrecht J. Lindsay KL, et al. Among authors: dienstag jl. Hepatology. 1996 Nov;24(5):1034-40. doi: 10.1002/hep.510240509. Hepatology. 1996. PMID: 8903371 Free article. Clinical Trial.
276 results